MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 29, 2005; DOI: 10.1124/mol.105.015909


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.015909v1
69/3/857    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.
Right arrow Articles by Quehenberger, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.
Right arrow Articles by Quehenberger, O.


Received for publication June 24, 2005.
Revised November 18, 2005.
Accepted for publication November 22, 2005.

The Amino-Terminus and the Third Extracellular Loop of CX3CR1 Contain Determinants Critical for Distinct Receptor Functions

Yiming Chen 1, Simone R Green 1, Felicidad Almazan 1, Oswald Quehenberger 1*

1 University of California, San Diego

* Address correspondence to: E-mail: oquehenberger{at}ucsd.edu

Abstract

The G protein-coupled receptor CX3CR1 is a specific receptor for the CX3C chemokine fractalkine. The aim of this study was to identify receptor elements that contribute independently to agonist binding and receptor activation. Targeted mutation of selected acidic amino acid residues demonstrated that the binding activity of CX3CR1 was critically dependent on the two negatively charged residues D25 and E254 located on the N-terminal domain and third extracellular loop, respectively. In addition, mutation of the uncharged polar residue Y14 in the amino terminus caused a reduction in the ligand binding affinity. In contrast, the three acidic residues E13, D16 and D266 did not contribute to ligand binding but were crucial for receptor activation. The mutant receptors E13A, D16A and D266A bound fractalkine with high affinity but were unable to induce signaling events necessary to support chemotaxis. These acidic residues may engage in electrostatic interactions with basic residues on fractalkine that are necessary for receptor function but not for binding. Our data are consistent with a model of chemokine receptor activation consisting of a multistep mechanism. Step one mediates the high affinity fractalkine binding involving Y14, D25 and E254. The initial interaction then triggers the engagement of E13, D16 and D266, necessary for CX3CR1 activation.


Key words: Chemotactic peptides, MAP Kinase, Receptor binding studies





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics